Abstract

Breast cancer is the most common type of cancer worldwide. However, the well-known molecular biomarkers are not enough to meet the needs of precision medicine. In search for novel targets in this regard, we reported ITSN1 (intersectin1) as one of the candidates through mRNA microarray analysis. In the present study, we reported that endocytic protein ITSN1-S exists not only in the cytoplasm but also in nuclei of breast cancer cells. ITSN1-S′ functional nuclear localization signal is within its residues 306–312. Its nuclear export signal (NES) resides within its SH3 domains. We also found, the interaction between the CC domain of nuclear ITSN1-S and the NT domain of nuclear DNA helicase II (NDH II) directly suppressed the DNA replication and nascent DNA synthesis by inhibiting the R-loops resolution in breast cancer cells. Furthermore, the interaction between the EH domains of cytoplasmic ITSN1-S and PI3KC2α inhibit cell migration and invasion by inactivating the PI3KC2α-AKT pathway. Our results were confirmed in both ITSN1 gene knockout cells and in vivo assays. Finally, our clinical data showed a potential application of the combined consideration of the cytoplasmic and nuclear ITSN1-S as an independent prognosis factor. In conclusion, our study revealed ITSN1-S′ novel positioning in the nuclei of breast cancer cells, its function in suppressing DNA replication, and its potential application in improved breast cancer prognosis.

Details

Title
Endocytic protein intersectin1-S shuttles into nucleus to suppress the DNA replication in breast cancer
Author
Zhang Huikun 1   VIAFID ORCID Logo  ; Guo Zhifang 1 ; Liu, Xiaoli 1 ; Zhao, Yawen 1 ; Chen Yongzi 1 ; Zhang, Ming 2 ; Fu, Li 3 ; Gu, Feng 3 ; Ma Yongjie 1   VIAFID ORCID Logo 

 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Department of Tumor Cell Biology, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Tianjin Medical University Cancer Institute and Hospital, Tianjin’s Clinical Research Center for Cancer, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Tianjin Medical University, Ministry of Education, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228) 
 University of Georgia, Department of Epidemiology and Biostatistics, Institute of Bioinformatics, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X) 
 Tianjin Medical University Cancer Institute and Hospital, Tianjin’s Clinical Research Center for Cancer, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Tianjin Medical University, Ministry of Education, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University Cancer Institute and Hospital, Department of Breast Cancer Pathology and Research Laboratory, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427) 
Publication year
2021
Publication date
Oct 2021
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2580182432
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.